A Study to Learn About the Study Medicine (Called TTI-622) in Japanese With Difficult to Manage Type of Lymphoma

• Status: Not yet recruiting
• Trial end date: 2023-12-31

Summary

The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called TTI-622) when taken for the treatment of lymphoma (a type of cancer that affects your body's infection-fighting cells, lymphocytes).

This study is seeking participants who:

• are 18 years of age or older

• have worsening and difficult to manage type of lymphoma

• Have adequately functioning organs

• are not on long term use of steroids which are given either by mouth or as shots

• have no major heart related disease etc.

All participants in this study will receive TTI-622 as an IV infusion (given directly into a vein) at the study clinic every week.

Participants will continue to receive TTI-622 until their progress of cancer worsens or the participants do not wish to take the study medicine.

The experiences of the people receiving the study medicine will be collected. This will help to understand if the study medicine TTI-622, is safe and can be given to Japanese people.

• Phase: Phase 1

Details

• Lead Sponsor: Pfizer